Immunogenicity and safety of concurrent or sequential administration of live, attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) and measles-mumps-rubella vaccine in infants 9–12 months of age in the Philippines: A non-inferiority Phase 4 randomized clinical trial

INTRODUCTION: Japanese encephalitis (JE) virus is the leading cause of viral encephalitis across temperate and tropical zones of Asia. The live attenuated SA 14-14-2 JE vaccine (CD-JEV) is one of three vaccines prequalified by the World Health Organization (WHO) to prevent JE. When incorporating a n...

Descripción completa

Detalles Bibliográficos
Autores principales: Capeding, Maria Rosario, Alberto, Edison, Feser, Jodi, Mooney, Jessica, Tang, Yuxiao, Audet, Susette A., Beeler, Judy A., Ellison, Damon W., Zhang, Lei, Letson, G. William, Neuzil, Kathleen M., Marfin, Anthony A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Regular paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509462/
https://www.ncbi.nlm.nih.gov/pubmed/33005887
http://dx.doi.org/10.1016/j.jvacx.2020.100074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509462/
https://www.ncbi.nlm.nih.gov/pubmed/33005887
http://dx.doi.org/10.1016/j.jvacx.2020.100074

Ejemplares similares